Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)
Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%
Bicycle Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Bicycle Therapeutics's price to sales ratio was 4.2× on Nov 11, 2026, against 18.3× a year earlier. Over the last 5 years it ranged from 4.2× to 132.3×, with a median of 29.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.2× | −13.1 |
| 2025 | Dec 31, 2025 | 17.3× | −8.9 |
| 2024 | Dec 31, 2024 | 26.2× | −4.7 |
| 2023 | Dec 29, 2023 | 30.9× | −27.5 |
| 2022 | Dec 30, 2022 | 58.4× | −73.9 |
| 2021 | Dec 31, 2021 | 132.3× | +100.5 |
| 2020 | Dec 31, 2020 | 31.8× | +14.2 |
| 2019 | Dec 31, 2019 | 17.6× | – |
See a number that looks wrong?